Druggable phosphatases in cancer and immune cells, with examples of their corresponding drugs. Structures of allosteric inhibitors targeting PP2A, PRL3, DUSP1/6, and SHP2 in cancer cells (left).

Innate immunity is a cornerstone of the body’s immediate defense against cancer, orchestrating the early recognition and response to tumor cells through key ...

Immunotherapy has transformed cancer care, offering a way to harness the body’s own immune system to fight tumors. But even with these advances, many patients still don’t respond. One major barrier to ...

Colorectal tumors that underwent somatic next-generation sequencing (NGS) for 154-168 genes in an in-house laboratory between 2015 and 2022 were retrospectively identified. Microsatellite instability ...

University of Cincinnati Cancer Center researchers will present abstracts at the American Association for Cancer Research Annual Meeting 2026 April 17 to 22 in San Diego.

QIMR Berghofer-led research in collaboration with Australian oncology company Kazia Therapeutics has found that combining the drug candidate paxalisib with immunotherapy triggered a molecular ...

JCO Precision Oncology Conversations features discussions with leading authors of JCO Precision Oncology articles, hosted by Dr. Abdul Rafeh Naqash. Join our experts in engaging conversations as they ...

A newly identified interaction between ovarian cancer cells and surrounding abdominal cells helps explain the cancer’s ...